logo

Search studies

54 studies found

LIH-PREDI-COVID
e6f84ce3-04f3-11ec-a683-d0577bab103e

PREDI-COVID participants` samples and data for COVIRNA

  • Types: Predi-Covid Participants` Samples And Data For Covirna

LUCENT-1 (NCT 03518086)
ELU-4-58F581-1

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  • Types: Clinical Trial Ncit:c71104

LuxPark
ELU-4-F67092-1

The cohort includes people with Parkinson’s disease, atypical parkinsonism, and healthy controls, who have their state of health regularly monitored by specialists over many years. The participants donate samples of body fluids such as blood or urine. They also take part in clinical examinations that analyze movement sequences and test their attention, memory, vision, speech, and sense of smell.

  • Types: Clinical Trial Ncit:c71104

MIBIPA
ELU-4-E34987-1

Non-invasive microbiome-derived multi-omic biomarkers for the early-stage detection and stratification of Parkinson's disease

  • Types: Clinical Trial Ncit:c71104

OncoTrack
dc9c42f0-147a-11eb-b51f-8c8590c45a21

fairplus stamp

OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantl...

  • Types: Observational Xenografts 3d Cell Cultures

OncoTrack study
ELU-4-24D114-1

OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantl...

  • Types: Clinical Trial Ncit:c71104

P2N ADPSOKO
e03298b0-91c8-11ed-97aa-acde48001122

  • Types: Biosamples Transcriptomics Methylome

PEI HUVEC-characterization study
ELU-4-4238C7-1

Within a broad characterization study, we analyzed activation, viability, cytokine secretion, and permeability of human umbilical vein endothelial cells (HUVECs) upon stimulation with different stimuli. In addition HUVEC-permeability was analyzed in a trans-well-based leakage assay upon stimulation in presence or absence of human peripheral blood mononuclear cells (PBMCs).

  • Types: In Vitro Study